Cell-type- and state-resolved transcriptomics uncovers distinct T cell and monocyte dysregulation in multiple sclerosis

Read full text
Authors: Tina Roostaei, Masashi Fujita, Hanane Touil, Pia Kivisäkk, Cristin McCabe, Parham Nejad, Afsana Sabrin, Frankie G. Garcia, Christiaan H. van Dorp, Daniel Felsky, Ioannis S. Vlachos, Daniel Hui
+14 more Jennifer Fransson, Will Macnair, Anna Williams, Lili Zhang, Wen Zhu, Zongqi Xia, Violetta Zujovic, Nikolaos A. Patsopoulos, Andrew J. Yates, Vijay Kuchroo, Tanuja Chitnis, Howard L. Weiner, Hans‐Ulrich Klein, Philip L. De Jager
Cited by: 1
References: 58

Abstract

Multiple sclerosis (MS) is a complex immune-mediated disorder with polygenic and multicellular underpinnings, necessitating cell-type-specific molecular studies to delineate dysregulated pathways. Here, we profile 1,075 transcriptomes from 167 patients with MS and 42 healthy participants across six peripheral immune cell-type-states. MS-associated transcriptional differences are more pronounced in primary (unstimulated) immune cells than in in vitro-stimulated counterparts. We identify shared and cell-type-specific transcriptional alterations at the level of genes, pathways, and co-expressed gene modules, prioritizing regulators, such as ZBTB16, across T cells and monocytes, and replicating six MS-associated modules in independent datasets. The top T cell module is enriched for MS susceptibility genes and affects proliferation. The top monocyte module implicates dysregulated TNF-α/NF-κB signaling, for which an in silico drug screen and in vitro validation nominate alvespimycin as a candidate modulator. Together, these findings define stable peripheral immune dysregulation signatures in MS that may serve as diagnostic or prognostic biomarkers in at-risk individuals.

Fields of Study & Subjects

Multiple Sclerosis Research Studies T-cell and B-cell Immunology vaccines and immunoinformatics approaches

Publication details

Journal / source
Cell Reports
Publisher
Elsevier BV
Volume
45
Issue
6
Pages
117417–117417
Publication date
1 June 2026
Language
EN